Document and Entity Information (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Mar. 16, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	AGILE THERAPEUTICS INC
Entity Central Index Key	0001261249
Document Type	10-K
Document Period End Date	Dec. 31, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 78.7
Entity Common Stock, Shares Outstanding		22,154,365
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 40,182,141	$ 2,119,646
Prepaid expenses	803,775	146,704
Total current assets	40,985,916	2,266,350
Property and equipment, net	12,046,267	11,963,079
Prepaid expenses, long-term	1,677,434
Deferred financing costs, net	98,401	157,499
Other assets	18,208	18,208
Total assets	54,826,226	14,405,136
Current liabilities:
Accounts payable	2,631,217	715,454
Accrued expenses	1,062,113	379,164
Loan payable, current portion	5,003,143	5,105,407
Warrant liability	296,048	644,478
Total current liabilities	8,992,521	6,844,503
Loan payable, long-term	9,827,758	9,769,528
Commitments and contingencies (Note 13)
Stockholders' equity (deficit):
Common stock, $.0001 par value, authorized 150,000,000 shares; 18,634,872 shares issued and outstanding as of December 31, 2014 and 109,321 shares issued and 103,536 shares outstanding as of December 31, 2013	1,864	10
Additional paid-in capital	170,395,934	46,872,801
Accumulated deficit	(134,391,851)	(118,314,383)
Total stockholders' equity (deficit)	36,005,947	(71,441,572)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	54,826,226	14,405,136
Series A-1, 8%, non-cumulative convertible preferred stock
Current liabilities:
Convertible preferred stock, $.0001 par value		898,305
Series A-2 convertible preferred stock
Current liabilities:
Convertible preferred stock, $.0001 par value		543,623
Series B, 8% non-cumulative, convertible preferred stock
Current liabilities:
Convertible preferred stock, $.0001 par value		44,928,382
Series C, 12% non-cumulative, convertible preferred stock
Current liabilities:
Convertible preferred stock, $.0001 par value		$ 22,862,367

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013 Series A-1, 8%, non-cumulative convertible preferred stock	Dec. 31, 2013 Series A-2 convertible preferred stock	Dec. 31, 2013 Series B, 8% non-cumulative, convertible preferred stock	Dec. 31, 2013 Series C, 12% non-cumulative, convertible preferred stock
Convertible preferred stock, par value (in dollars per share)			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized			284,743	99,178	4,510,066	2,711,734
Convertible preferred stock, issued			137,787	66,116	4,510,066	1,578,400
Convertible preferred stock, outstanding			137,787	66,116	4,510,066	1,578,400
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	150,000,000
Common stock, issued	18,634,872	109,321
Common stock, outstanding	18,634,872	103,536

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

Statements of Operations (USD $)	12 Months Ended
Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating expenses:
Research and development	$ 13,364,704	$ 9,154,484	$ 17,386,961
General and administrative	5,150,512	3,573,893	5,929,890
Total operating expenses	18,515,216	12,728,377	23,316,851
Loss from operations	(18,515,216)	(12,728,377)	(23,316,851)
Other income (expense)
Interest expense	(1,565,730)	(1,512,911)	(140,051)
Interest income	2,563	1,658	25,762
Change in fair value of warrants	348,430	(80,990)	171,013
Loss before benefit from income taxes	(19,729,953)	(14,320,620)	(23,260,127)
Benefit from income taxes	3,652,485
Net loss	(16,077,468)	(14,320,620)	(23,260,127)
Beneficial conversion charge			(600,000)
Net loss attributable to common stockholders	$ (16,077,468)	$ (14,320,620)	$ (23,860,127)
Net loss per share (basic and diluted) (in dollars per share)	$ (1.41)	$ (289.39)	$ (603.78)
Weighted-average shares outstanding (basic and diluted) (in shares)	11,394,971	49,486	39,518

Statements of Convertible Preferred Stock and Changes in Stockholders' Equity (Deficit), Stockholders' Equity (Deficit) (USD $)	Common stock Convertible Promissory Notes, April 2014	Common stock Redeemable Convertible Preferred Stock	Common stock Initial public offering	Common stock	Additional Paid-in Capital Convertible Promissory Notes, April 2014	Additional Paid-in Capital Redeemable Convertible Preferred Stock	Additional Paid-in Capital Initial public offering	Additional Paid-in Capital	Deficit Accumulated during the Development Stage	Convertible Promissory Notes, April 2014	Redeemable Convertible Preferred Stock	Initial public offering	Total
Balance at Dec. 31, 2011				$ 4				$ 44,119,890	$ (80,133,636)				$ (36,013,742)
Balance (in shares) at Dec. 31, 2011				45,303
Increase (decrease) in stockholders' equity (deficit)
Share based compensation-stock options								665,454					665,454
Deemed dividends								600,000	(600,000)
Net loss									(23,260,127)				(23,260,127)
Balance at Dec. 31, 2012				4				45,385,344	(103,993,763)				(58,608,415)
Balance (in shares) at Dec. 31, 2012				45,303
Increase (decrease) in stockholders' equity (deficit)
Share based compensation-stock options								1,337,857					1,337,857
Issuance of common stock for employee bonuses				1				79,508					79,509
Issuance of common stock for employee bonuses (in shares)				11,981
Issuance of common stock upon exercise of options				5				70,092					70,097
Issuance of common stock upon exercise of options (in shares)				52,037
Net loss									(14,320,620)				(14,320,620)
Balance at Dec. 31, 2013				10				46,872,801	(118,314,383)				(71,441,572)
Balance (in shares) at Dec. 31, 2013				109,321
Increase (decrease) in stockholders' equity (deficit)
Share based compensation-stock options								1,380,713					1,380,713
Issuance of common stock for employee bonuses				1				79,999					80,000
Issuance of common stock for employee bonuses (in shares)				9,983
Conversion of preferred stock to common stock		882				69,231,796					69,232,678
Conversion of preferred stock to common stock (in shares)		8,803,547
Conversion of notes and accrued interest	50				3,020,617					3,020,667
Conversion of notes and accrued interest (in shares)	503,450
Common stock issued, net of expenses			917				49,742,724					49,743,641
Issuance of stock (in shares)			9,166,667
Issuance of common stock upon exercise of options				4				67,284					67,288
Issuance of common stock upon exercise of options (in shares)				41,904
Net loss									(16,077,468)				(16,077,468)
Balance at Dec. 31, 2014				$ 1,864				$ 170,395,934	$ (134,391,851)				$ 36,005,947
Balance (in shares) at Dec. 31, 2014				18,634,872

Statements of Convertible Preferred Stock and Changes in Stockholders' Equity (Deficit), Convertible Preferred Stock (USD $)	Convertible Promissory Notes July 2012 Series C, 12% non-cumulative, convertible preferred stock Series C Preferred Stock Purchase Agreement	Redeemable Convertible Preferred Stock Series A-1, 8%, non-cumulative convertible preferred stock	Redeemable Convertible Preferred Stock Series A-2 convertible preferred stock	Redeemable Convertible Preferred Stock Series B, 8% non-cumulative, convertible preferred stock	Redeemable Convertible Preferred Stock Series C, 12% non-cumulative, convertible preferred stock	Series A-1, 8%, non-cumulative convertible preferred stock	Series A-2 convertible preferred stock	Series B, 8% non-cumulative, convertible preferred stock Series B Preferred Stock financing, March 2012 closing	Series B, 8% non-cumulative, convertible preferred stock	Series C, 12% non-cumulative, convertible preferred stock Series C Preferred Stock Purchase Agreement	Series C, 12% non-cumulative, convertible preferred stock	Total
Balance at Dec. 31, 2011						$ 898,305	$ 543,623		$ 42,391,758
Balance (in shares) at Dec. 31, 2011						137,787	66,116		4,256,067
Increase (decrease) in temporary equity
Issuance of convertible preferred stock, net of offering costs								2,536,624		16,778,538
Issuance of stock (in shares)								253,999		1,127,746
Conversion of promissory notes and accrued interest	6,083,829
Conversion of notes and accrued interest (in shares)	450,654
Balance at Dec. 31, 2012						898,305	543,623		44,928,382		22,862,367
Balance (in shares) at Dec. 31, 2012						137,787	66,116		4,510,066		1,578,400
Balance at Dec. 31, 2013						898,305	543,623		44,928,382		22,862,367
Balance (in shares) at Dec. 31, 2013						137,787	66,116		4,510,066		1,578,400
Increase (decrease) in temporary equity
Conversion of preferred stock to common stock		$ (898,305)	$ (543,623)	$ (44,928,382)	$ (22,862,367)							$ (69,232,677)
Conversion of preferred stock to common stock (in shares)		(137,787)	(66,116)	(4,510,066)	(1,578,400)
Balance at Dec. 31, 2014

- Definition

+ References+ Details

Statements of Cash Flows (USD $)	12 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	$ (16,077,468)	$ (14,320,620)	$ (23,260,127)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12,551	11,876	23,662
Noncash stock bonus	80,000	79,509
Noncash stock based compensation	1,380,713	1,337,857	665,454
Noncash interest	185,731	132,911	83,829
Change in fair value of warrants	(348,430)	80,990	(171,013)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,334,504)	107,399	(33,792)
Accounts payable and accrued expenses	2,598,712	(448,748)	(275,958)
Net cash used in operating activities	(14,502,695)	(13,018,826)	(22,967,945)
Cash flows from investing activities
Acquisition of property and equipment	(95,739)	(4,945,379)	(6,692,981)
Net cash used in investing activities	(95,739)	(4,945,379)	(6,692,981)
Cash flows from financing activities
Proceeds from convertible bridge notes	3,000,000		6,000,000
Proceeds from issuance of term loan			15,000,000
Proceeds from issuance of preferred stock, net of offering costs			19,315,162
Proceeds from issuance of common stock in initial public offering, net of offering costs	49,743,641
Cash paid for financing costs	(150,000)		(202,499)
Proceeds from exercise of stock options	67,288	70,097
Net cash provided by financing activities	52,660,929	70,097	40,112,663
Net increase (decrease) in cash and cash equivalents	38,062,495	(17,894,108)	10,451,737
Cash and cash equivalents, beginning of period	2,119,646	20,013,754	9,562,017
Cash and cash equivalents, end of period	40,182,141	2,119,646	20,013,754
Supplemental disclosure of noncash financing activities
Interest paid	1,380,000	1,380,000	56,222
Supplemental cash flow information
Conversion of preferred stock into common stock	69,232,677
Convertible Promissory Notes, April 2014
Supplemental cash flow information
Conversion of promissory notes and accrued interest	$ 3,020,667

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Dec. 31, 2014
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Nature of Operations Agile Therapeutics, Inc. (the "Company") was incorporated in Delaware on December 22, 1997. The Company is engaged in research and development of transdermal patch technology for use in contraception. The Company's activities since inception have consisted principally of raising capital, and performing research and development. The Company is headquartered in Princeton, New Jersey. The Company is devoting substantially all of its efforts toward research and development of its transdermal patch for use in contraception, and raising capital. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies. The Company has incurred losses each year since inception. As of December 31, 2014, the Company had an accumulated deficit of approximately $134.4 million. The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see Note 9), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. The Company expects to continue to incur net losses into the foreseeable future. As of December 31, 2014, the Company had cash and cash equivalents of $40.2 million. Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.

Summary of Significant Accounting Polices

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Polices

Summary of Significant Accounting Polices

2. Summary of Significant Accounting Polices

Basis of Presentation

The accompanying financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.

Use of Estimates

The preparation of the Company's financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.

Stock Split

On May 5, 2014, the Company effected a 1.4-for-1 stock split of the Company's common stock. All share and per share amounts of common stock contained in the Company's financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders' deficit reflects the stock split by reclassifying from "Additional paid-in Capital" to "Common Stock" in an amount equal to the par value of the increased shares resulting from the stock split.

Cash and Cash Equivalents

The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations.

The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.

Fair Value of Financial Instruments

In accordance with ASC 825, Financial Instruments, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note 3).

Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.

Property and Equipment

Property and equipment, consisting of manufacturing, office and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line, method over the estimated useful lives of the assets.

Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Improvements and additions are capitalized in accordance with Company policy.

Long-Lived Assets

In accordance with ASC 360, Property, Plant and Equipment, the Company's policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Management does not believe that there has been any impairment of the carrying value of any long-lived assets as of December 31, 2014.

Research and Development Expense

Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development.

In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received.

Deferred Financing Costs

Costs directly attributable to the Company's term loan (see Note 8) are deferred and capitalized. These costs represent legal fees and other costs related to the term loan and are being amortized over the term of the loan. Amortization of deferred financing costs charged to interest expense was $59,100, $45,000 and $0 for the years ended December 31, 2014, 2013 and 2012, respectively.

Concentrations of Credit Risk

Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in business checking and money market accounts in United States financial institutions the balances of which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risks on cash and cash equivalents. The Company has no financial instruments with off-balance sheet risk of accounting loss.

Warrants

The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, Distinguishing Liabilities from Equity. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer's equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized in the statement of operations.

In connection with the completion of the Company's initial public offering in May 2014, the warrants to purchase shares of Series A-1 and Series A-2 preferred stock expired unexercised and the warrants to purchase shares of Series C preferred stock automatically converted into warrants to purchase shares of common stock. These common stock warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period. As of December 31, 2014, there were outstanding 62,505 warrants to purchase common stock at $6.00 per share. These warrants expire on December 14, 2019.

Income Taxes

The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of December 31, 2014 that qualifies for either recognition or disclosure in the financial statements under this guidance.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing models. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.

Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.

Prior to May 22, 2014, the Company utilized various methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its stock. The methodologies included an option pricing method and a probability-weighted expected return methodology that determined an estimated value under an initial public offering (IPO) scenario and a sale scenario based upon an assessment of the probability of occurrence of each scenario. Each valuation methodology includes estimates and assumptions that require the Company's judgment. These estimates include assumptions regarding future performance, including the successful completion of clinical trials and the time to completing an IPO or sale of the Company. As with any valuation, significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, which is the business of developing its transdermal patch for use in contraception.

Comprehensive Income

Effective January 1, 2012, an update to an accounting standard was issued that requires all non-owner changes in stockholders' equity to be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This update was applied retrospectively. The Company adopted this pronouncement and elected to present a separate statement of comprehensive income. The Company did not incur any components of comprehensive income for the periods presented and therefore, did not include a statement of comprehensive income in the financial statements.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):

	Year Ended December 31,
	2014		2013		2012
Convertible preferred stock		—		6,292,369		6,292,369
Convertible preferred stock warrants		—		205,020		205,020
Common stock warrants		62,505		—		—
Common stock options		1,817,548		1,163,621		1,341,731

Total		1,880,053		7,661,010		7,839,120

Recent Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP. Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements. A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business. Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No. 2014-10. ASU No. 2014 is effective for fiscal years beginning after December 15, 2014, with early adoption permitted. Retrospective application is required for the elimination of incremental DSE disclosures. Prior to the issuance of ASU No. 2014-10, the Company had met the definition of a DSE since its inception. The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with its Quarterly Report on Form 10-Q for the period ended June 30, 2014.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Measurements

Fair Value Measurements

3. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

•	Level 1—Quotes prices in active markets for identical assets and liabilities. The Company's Level 1 assets and liabilities consist of cash and cash equivalents.
•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities.
•	Level 3—Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company's Level 3 liabilities consist of the warrant liability.

The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.

The following table sets forth the Company's financial instruments measured at fair value by level within the fair value hierarchy as of December 31, 2014 and 2013.

	Level 1		Level 2		Level 3
2014
Assets:
Cash equivalents	$	40,135,102	$	—	$	—

Total assets at fair value	$	40,135,102	$	—	$	—


Liabilities:
Common stock warrants		—		—		296,048

Total liabilities at fair value	$	—	$	—	$	296,048

The significant assumptions used in preparing the option pricing model for valuing the Company's warrants as of December 31, 2014 include (i) volatility (104.8%), (ii) risk free interest rate of 1.68% (estimated using treasury bonds with a 5 year life), (iii) strike price ($6.00) for the common stock warrants, (iv) fair value of common stock ($6.14) and (v) expected life (five years)

The following is a rollforward of the fair value of Level 3 warrants:

Beginning balance at December 31, 2011	$	521,525
Issuance of Series C warrants		212,976

Change in fair value		(171,013	)

Ending balance at December 31, 2012		563,488
Change in fair value		80,990

Ending balance at December 31, 2013		644,478
Expiration of Series A-1 and Series A-2 warrants		(493,361	)
Change in fair value		144,931

Ending balance at December 31, 2014	$	296,048

	Level 1		Level 2		Level 3
2013
Assets:
Cash equivalents	$	2,066,156	$	—	$	—

Total assets at fair value	$	2,056,156	$	—	$	—


Liabilities:
Series A-1 warrants	$	—	$	—	$	438,978
Series A-2 warrants		—		—		64,537
Series C warrants		—		—		140,963

Total liabilities at fair value	$	—	$	—	$	644,478

The significant assumptions used in preparing the option pricing model for valuing the Company's warrants as of December 31, 2013 include (i) volatility (104.8%), (ii) risk free interest rate of 1.94% (estimated using treasury bonds with a 6 year life), (iii) strike price ($10.00) for the Series A-1 and Series A-2 warrants and $15.00 for the Series C warrants, (iv) fair value of Series A-1 preferred stock ($4.17), Series A-2 preferred stock ($2.91) and Series C preferred stock ($7.63) and (v) expected life (six years).

There were no transfers between Level 1, 2 or 3 during 2014 or 2013. If the Company's estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Prepaid Expenses

12 Months Ended

Dec. 31, 2014

Prepaid Expenses

Prepaid Expenses

4. Prepaid Expenses

Prepaid expenses consist of the following:

	December 31
	2014		2013
Prepaid clinical trial expense	$	1,677,434	$	—
Prepaid insurance		761,842		48,055
Other		41,933		98,649

Total prepaid expenses	$	2,481,209	$	146,704


Prepaid expenses, short-term	$	803,775	$	146,704
Prepaid expenses, long-term		1,677,434		—

Total prepaid expenses	$	2,481,209	$	146,704

Prepaid expenses, long-term represents non-refundable advances to the Company's clinical research organization which will be applied against final invoices in accordance with the contractual terms of the arrangement.

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property and Equipment

Property and Equipment

5. Property and Equipment

	December 31
	December 31						Estimated Life
	2014			2013			Estimated Life
Office equipment	$	54,468		$	51,723		3 - 10 years
Computer equipment		95,145			65,746		3 years
Manufacturing equipment		12,182,297			12,118,702		5 years

		12,331,910			12,236,171
Less: accumulated depreciation		(285,643	)		(273,092	)

Property and equipment, net	$	12,046,267		$	11,963,079

As December 31, 2014 and 2013, manufacturing equipment includes approximately $12.0 million and $11.9 million, respectively, of equipment which is in the process of being constructed and qualified and is not currently being depreciated.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Accrued Liabilities

12 Months Ended

Dec. 31, 2014

Accrued Liabilities

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consist of the following:

	December 31
	2014		2013
Employee bonuses	$	665,050	$	238,941
Accrued clinical trial costs		254,333		—
Other		142,730		140,223

Total accrued liabilities	$	1,062,113	$	379,164

Convertible Note Financing (Convertible notes, Convertible Promissory Notes, April 2014)	12 Months Ended
	Dec. 31, 2014
Convertible notes \| Convertible Promissory Notes, April 2014
Debt
Convertible Note Financing	7. Convertible Note Financing On April 28, 2014, the Company and certain of the Company's existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0 million. The Company issued Convertible Promissory Notes (the "Notes") to evidence its payment obligations with respect to the $3.0 million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes are convertible into unregistered equity securities of the Company upon the occurrence of events stated therein. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in an underwritten public offering (see Note 9). The Notes were subordinate to the Company's term loan with Oxford Finance LLC.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Term Loan (Secured term loan, Oxford Finance loan, as amended)

12 Months Ended

Dec. 31, 2014

Secured term loan | Oxford Finance loan, as amended

Debt

Term Loan

8. Term Loan

In December 2012, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC ("Oxford Finance") pursuant to which the Company borrowed a total of $15.0 million (the "Term Loan") from Oxford. The Term Loan accrues interest at a fixed annual interest rate equal to 9.20% (Three-month U.S. Libor rate of 0.47% plus 8.73%).

In January 2014, the Company amended its Loan Agreement with Oxford Finance whereby the interest only period was extended for an additional twelve months (through January 1, 2015) as a result of the Company's convertible note financing (see Note 7) and completion of the Company's initial public offering (see Note 9). In connection with the amendment to the Loan Agreement the Company has paid Oxford Finance a total of $150,000. The $150,000 has been offset against the amount of the loan and is being amortized to interest expense.

Interest on the Term Loan is payable monthly and principal is due in 30 equal consecutive monthly installments beginning on February 1, 2015 and ending on July 1, 2017. In addition, the Company is required to make a final payment of $675,000 on the maturity date of the Term Loan (July 1, 2017).

The Company may prepay all, but not less than all, of the Term Loan subject to a prepayment premium of 2% of the outstanding principal during the first twenty-four months of the Term Loan. From months twenty-five to loan maturity the prepayment premium is 0.75% of the outstanding principal. The obligations of the Company under the Loan Agreement are secured with a blanket lien on all assets of the Company, excluding its intellectual property assets. Under the Loan Agreement, the Company is subject to specified affirmative and negative covenants. The Loan Agreement provides, that, upon the occurrence of certain events of default, the Company's obligations under the Loan Agreement may be automatically accelerated, whereupon the Company's obligations under the Loan Agreement shall be immediately due and payable. At December 31, 2014, the Company believes it is in compliance with the Loan Agreement.

In connection with the Loan Agreement, the Company issued Oxford Finance warrants to purchase 25,002 shares of Series C Preferred Stock at $15.00 per share. The value of these warrants was calculated to be approximately $213,000 which is being accreted to interest expense ratably over the term of the loan. In connection with its initial public offering (see Note 9), the Series C preferred stock warrants were converted into 62,505 warrants to purchase common stock at $6.00 per share. These warrants expire on December 14, 2019.

Interest expense on the Term Loan including the accretion of the value of the related warrants and amortization of the deferred financing costs was approximately $1,545,100, $1,472,300 and $0 for the years ended December 31, 2014, 2013 and 2012, respectfully.

The annual maturities of the Term Loan, as of December 31, 2014, are as follows:

2015	$	5,105,407
2016		6,081,174
2017		3,813,419

Total	$	15,000,000

In February 2015, the Company terminated the Loan Agreement with Oxford (see Note 14)

- Definition

+ References+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Equity

Stockholders' Equity

9. Stockholders' Equity

Initial Public Offering and Related Transactions

On May 29, 2014, the Company completed its initial public offering selling 9,166,667 shares of common stock at $6.00 per share. Proceeds from the Company's initial public offering, net of underwriting discounts and commissions and other offering costs, were $49.7 million.

In addition, each of the following occurred in connection with the completion of the Company's IPO on May 29, 2014:

•	the conversion of all outstanding shares of convertible preferred stock into 8,809,325 shares of the Company's common stock; and
•	the conversion of the aggregate principal amount of $3.0 million and accrued interest under the Company's outstanding convertible subordinated promissory notes into 503,450 shares of the Company's common stock.

On May 7, 2014, the Company filed an amendment to its amended and restated certificate of incorporation which, among other things, revised the automatic conversion provision relating to the Series C Preferred Stock, Series B Preferred Stock, Series A-1 Preferred Stock and Series A-2 Preferred Stock. Following such amendment, the Series C, the Series B, the Series A-1 and A-2 Preferred Stock automatically converted into shares of common stock at the then effective conversion price upon:

(i) the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, covering the offer and sale of common stock from which the Company receives gross proceeds of at least $45,000,000 or (ii) the affirmative vote of the holders of at least a majority of the voting power the Series C Preferred Stock, the Series B Preferred Stock and the Series A-1 Preferred Stock, respectively, after first giving effect, if in conjunction with a public offering which does not meet the standards set forth in clause (i) above, to any adjustment of the conversion price for each series of preferred stock to which it would otherwise be entitled by virtue of such public offering.

On May 29, 2014, the Company filed an amended and restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware in connection with the closing of the Company's initial public offering of shares of its common stock. The Company's board of directors (the "Board") and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company's initial public offering.

The Restated Certificate amends and restates in its entirety the Company's second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: (i) authorizes 150,000,000 shares of common stock; (ii) eliminates all references to the previously existing series of preferred stock; (iii) authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iv) provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company's stockholders; (v) provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (vi) provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and (vii) requires that any action instituted against the Company's officers or directors in connection with their service to the Company be brought in the State of Delaware.

Convertible Preferred Stock (Prior to IPO)

Prior to its conversion in the IPO, the Company's convertible preferred stock was classified as temporary equity on its balance sheets instead of stockholders' (deficit) in accordance with authoritative guidance for the classification and measurement or redeemable securities. Upon certain change in control events that were outside of the Company's control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.

Sales of Convertible Preferred Stock

In March 2012, the Company completed its Series B Preferred Stock financing by issuing the remaining 253,999 shares of Series B convertible preferred stock at a price of $10.00 per share resulting in net proceeds of approximately $2.5 million.

In July 2012, the Company entered into a Series C Preferred Stock Purchase Agreement (the "Series C Agreement") to issue a total of 2,711,734 shares of Series C Preferred Stock at a purchase price per share of $15.00. In July 2012, the Company issued the initial tranche of 1,578,400 shares of Series C Convertible Preferred Stock and received net proceeds of approximately $22.9 million.

The Company evaluated each series of its preferred stock and determined that each individual series is considered an equity host under ASC 815, Derivatives and Hedging. In making this determination, the Company's analysis followed the whole instrument approach which compares an individual feature against the entire preferred stock instrument which includes that feature. The Company's analysis was based on a consideration of the economic characteristics and risks of each series of preferred stock. More specifically, the Company evaluated all of the stated and implied substantive terms and features, including (i) whether the preferred stock included redemption features, (ii) how and when any redemption features could be exercised, (iii) whether the holders of preferred stock were entitled to dividends, (iv) the voting rights of the preferred stock and (v) the existence and nature of any conversion rights. As a result of the Company's conclusion that the preferred stock represents an equity host, the conversion feature of all series of preferred stock is considered to be clearly and closely related to the associated preferred stock host instrument. Accordingly, the conversion feature of all series of preferred stock is not considered an embedded derivative that requires bifurcation.

The Company accounts for potentially beneficial conversion features under ASC 470-20, Debt with Conversion and Other Options. At the time of each of the issuances of convertible preferred stock, the Company's common stock into which each series of the Company's preferred stock is convertible had an estimated fair value less than the effective conversion prices of the convertible preferred stock. Therefore, there was no intrinsic value on the respective commitment dates for the convertible preferred stock instruments.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Equity Incentive Plans

12 Months Ended

Dec. 31, 2014

Equity Incentive Plans

Equity Incentive Plans

10. Equity Incentive Plans

The Company had granted stock options under an amended and restated 1997 Equity Incentive Plan (the "1997 Plan") and a 2008 Equity Incentive Plan (the "2008 Plan"). The plans provided for the granting of incentive and nonstatutory options and stock awards to consultants, directors, officers and employees. Such options are exercisable for a period of ten years and generally vest over a four-year period. In conjunction with the adoption of the 2008 Plan in April 2008, no additional grants were made from the 1997 Plan and issued options from the 1997 Plan remain outstanding. In 2014, the Company's Board of Directors approved the 2014 Equity Incentive Plan (the "2014 Plan"). The 2014 Plan is the successor to the Company's 2008 Plan and 1997 Plan. In conjunction with the adoption of the 2014 Plan in 2014, no additional grants were made from the 2008 Plan and options from the 1997 Plan and the 2008 Plan remain outstanding. As of December 31, 2014, there were 395,598 shares available for future grant under the 2014 Plan.

Through December 31, 2014, the Company granted options to certain employees and nonemployees to purchase shares of common stock at exercise prices ranging from $0.71 to $1,928.57 per share. The Company recorded non cash stock based compensation expense of $1,380,713, $1,337,857 and $665,454 for the years ended December 31, 2014, 2013 and 2012, respectively, based on the fair market value of the options granted at the grant date as determined using a Black-Scholes option pricing model. Stock-based compensation expense was as follows:

	Year Ended December 31,
	2014		2013		2012
Employee	$	1,184,864	$	475,897	$	509,747
Non-employee		195,849		861,960		155,707

Total	$	1,380,713	$	1,337,857	$	665,454

Stock-based compensation expense related to stock options was allocated as follows:

	Year Ended December 31,
	2014		2013		2012
Research and development	$	617,061	$	861,908	$	343,990
General and administrative		763,652		475,949		311,464

Total stock-based compensation expense	$	1,380,713	$	1,337,857	$	665,454

The following assumptions were used to compute employee stock-based compensation under the Black-Scholes option pricing model:

	2014			2013			2012
Risk-free interest rate		1.84	%		1.73	%		0.80	%
Expected volatility		104.8	%		104.8	%		105.2	%
Expected dividend yield		0	%		0	%		0	%
Expected life (in years)		6.25			6.25			6.25

Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.

Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.

Expected volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on comparable companies in the biotechnology and pharmaceutical industries.

Expected term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historic exercise behavior, management determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.

Forfeitures. The Company reduces stock-based compensation expense for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

As of December 31, 2014, the unrecorded deferred stock-based compensation balance related to stock options was approximately $5.3 million and will be recognized over an estimated weighted-average amortization period of 1.98 years. The weighted average grant date fair value of options granted during the year ended December 31, 2014 was $7.00.

The following table summarizes the options outstanding, options vested and the options exercisable as of December 31, 2014 and 2013:

	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2012		649,275		$	2.47	8.8 years
Options granted		692,456			4.38
Options cancelled/forfeited		—			—

Options outstanding at December 31, 2012		1,341,731		$	3.41	8.9 years
Options granted		27,534			4.38
Options exercised		(52,037	)		1.35
Options cancelled/forfeited		(153,607	)		4.10

Options outstanding at December 31, 2013		1,163,621			3.44	7.9 years
Options granted		712,570			8.76
Options exercised		(41,904	)		1.61
Options cancelled/forfeited		(16,739	)		4.65

Options outstanding at December 31, 2014		1,817,548			5.56	7.9 years	$	3,363,242


Options exercisable at December 31, 2014		923,301			3.34	6.8 years	$	2,999,337


Vested and expected to vest at December 31, 2014		1,817,548			5.56	7.9 years

Intrinsic value in the above table was calculated as the difference between the Company's estimated stock price at December 31, 2014, of $6.14, and the exercise price, multiplied by the number of options. Intrinsic value for options exercised during 2014 amounts to $208,979.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Taxes

Income Taxes

11. Income Taxes

As of December 31, 2014, the Company had available net operating loss carryforwards ("NOL") of approximately $123.3 million and $82.1 million for federal and state income tax reporting purposes, respectively, which are available to offset future federal and state taxable income, if any, through 2034. The Company also has research and development tax credit carryforwards of approximately $2.9 million and $1.1 million for federal and state income tax reporting purposes, respectively, which are available to reduce federal income taxes, if any, through 2034 and state income taxes, if any, through 2029.

The Internal Revenue Code of 1986, as amended (the "Code") provides for a limitation on the annual use of NOL and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes, as defined by the Code that could significantly limit the Company's ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company's formation, due to the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financings. Accordingly, the Company's ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal and state income tax purposes.

The Company does not have any significant unrecognized tax benefits.

As of December 31, 2014, the Company has not accrued interest or penalties related to uncertain tax positions. The Company's tax returns for the years ended December 31, 2011 through December 31, 2013 are still subject to examination by major tax jurisdictions.

For all years through December 31, 2014, the Company generated research credit but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company's research and development credit carryforwards; however, until a study is completed and any adjustment in known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company's research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below:

	December 31
	2014			2013
Deferred tax assets:
Net operating loss carryforwards	$	46,853,000		$	41,800,000
Research credit carryforward		3,683,000			3,110,000
Stock options and other		795,000			481,000

Total gross deferred tax assets		51,331,000			45,391,000
Valuation allowance for deferred tax assets		(51,331,000	)		(45,391,000	)

Net deferred tax assets	$	—		$	—

The gross deferred tax assets and the valuation allowance shown above represent the items which reduce the income tax benefit which would result from applying the federal statutory tax rate to the pretax loss and cause no income tax expense or benefit to be recorded for the years ended December 31, 2014 and 2013.

The net change in the valuation allowance for the years ended December 31, 2014 and 2013 was an increase of $4.7 million and $6.0 million, respectively, related primarily to net operating losses incurred by the Company which are not currently deductible.

A reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows:

	December 31,
	2014			2013			2012
Federal income tax at statutory rate		34	%		34	%		34	%
State income tax benefit, net of federal benefit		6.0	%		5.7	%		5.8	%
Research and development tax credits		3.0	%		2.7	%		0.4	%
Other		—	%		(1.4	)%		(0.5	)%
Increase to valuation allowance		(24.0	)%		(41.0	)%		(39.7	)%

Effective income tax rate		19.00	%		0.00	%		0.00	%

Sale of New Jersey Net Operating Losses

The Company received approval to sell a portion of the Company's New Jersey net operating losses (NOLs) as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other companies. On February 27, 2014, the Company completed the sale of NOLs totaling approximately $39.1 million and research and development credits totaling approximately $0.4 million for net proceeds of approximately $3.6 million. Such proceeds are reflected as a tax benefit for year ended December 31, 2014.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions
Related Party Transactions	12. Related Party Transactions Effective March 17, 2014, one of the Managing Partners of SmartPharma LLC, or SmartPharma, an entity which provides commercial and business development consulting services to the Company, was appointed Chief Commercial Officer. In connection with the appointment of this individual as Chief Commercial Officer, the Company amended its consulting agreement with SmartPharma to remove this individual from the list of persons providing service under the consulting agreement. SmartPharma invoiced the Company $126,500 of fees for the year ended December 31, 2014.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies.

Commitments and Contingencies

13. Commitments and Contingencies

Operating Leases

The Company leases approximately 7,000 square feet of office space in Princeton, NJ. The current term of the lease is for a two year period ending on November 30, 2015. The Company has an option to renew the lease for a term of three years.

Rent expense was $159,042, $141,854 and $113,962 for the years ended December 31, 2014, 2013 and 2012, respectively.

Future minimum annual lease commitments under the noncancelable operating lease in effect as of December 31, 2014 are as follows:

2015

148,729

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events
Subsequent Events	14. Subsequent Events The following events occurred subsequent to December 31, 2014 through the date the financial statements was available to be issued. Private Placement In January 2015, the Company completed a private placement of approximately 3.4 million shares of common stock at $5.85 per share. Proceeds from the Company's private placement, net of commissions and other offering costs were $19.3 million. Loan and Security Agreement In February 2015, the Company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. ("Hercules") for a term loan of up to $25.0 million. A first tranche of $16.5 million was funded upon execution of the loan agreement, approximately $15.5 million of which was used to repay the Company's existing term loan with Oxford (see Note 8). The Company is scheduled to make interest only payments on the loan until July 1, 2016, which period may be extended under certain circumstances. Under the terms of the loan agreement, the Company may, but is not obligated to, draw an additional tranche of up to $8.5 million prior to July 1, 2016, subject to the achievement of certain clinical milestones, which may be extended to December 31, 2016 under certain circumstances. In connection with the loan agreement, the Company issued Hercules a warrant to purchase 180,274 shares of the Company's common stock at an exercise price of $5.89 per share and granted Hercules the right participate in future equity financings in an amount up to $2.0 million while the loan and warrant are outstanding.

Quarterly Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure

Quarterly Data (Unaudited)

15. Quarterly Data (Unaudited)

The following tables summarize the quarterly results of operations for each of the quarters in 2014 and 2013. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.

	March 31, 2014		June 30, 2014			September 30, 2014			December 31, 2014
Total revenue	$	—	$	—		$	—		$	—
Operating expenses	$	2,447,626	$	3,494,710		$	6,048,884		$	6,523,996
Net income (loss)	$	839,293	$	(3,718,401	)	$	(6,353,362	)	$	(6,844,998	)
Basic net income (loss) per common share	$	0.10	$	(0.46	)	$	(0.34	)	$	(0.37	)
Diluted net income (loss) per common share	$	0.01	$	(0.46	)	$	(0.34	)	$	(0.37	)

	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Total revenue	$	—		$	—		$	—		$	—
Operating expenses	$	4,228,361		$	3,249,070		$	3,321,389		$	1,929,557
Net income (loss)	$	(4,605,416	)	$	(3,619,879	)	$	(3,690,955	)	$	(2,404,370	)
Basic net income (loss) per common share	$	(109.18	)	$	(70.29	)	$	(71.67	)	$	(45.68	)
Diluted net income (loss) per common share	$	(109.18	)	$	(70.29	)	$	(71.67	)	$	(45.68	)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Summary of Significant Accounting Polices (Polices)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Polices

Basis of Presentation

Use of Estimates

Stock Split

Cash and Cash Equivalents

The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.

Fair Value of Financial Instruments

Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.

Property and Equipment

Long-Lived Assets

Research and Development Expense

Deferred Financing Costs

Concentrations of Credit Risk

Warrants

Income Taxes

Stock-Based Compensation

Segment Information

Comprehensive Income

Net Loss Per Share

	Year Ended December 31,
	2014		2013		2012
Convertible preferred stock		—		6,292,369		6,292,369
Convertible preferred stock warrants		—		205,020		205,020
Common stock warrants		62,505		—		—
Common stock options		1,817,548		1,163,621		1,341,731

Total		1,880,053		7,661,010		7,839,120

Recent Accounting Pronouncements

Summary of Significant Accounting Polices (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Polices

Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share

	Year Ended December 31,
	2014		2013		2012
Convertible preferred stock		—		6,292,369		6,292,369
Convertible preferred stock warrants		—		205,020		205,020
Common stock warrants		62,505		—		—
Common stock options		1,817,548		1,163,621		1,341,731

Total		1,880,053		7,661,010		7,839,120

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Measurements

Schedule of financial instruments measured at fair value by level within fair value hierarchy

	Level 1		Level 2		Level 3
2014
Assets:
Cash equivalents	$	40,135,102	$	—	$	—

Total assets at fair value	$	40,135,102	$	—	$	—


Liabilities:
Common stock warrants		—		—		296,048

Total liabilities at fair value	$	—	$	—	$	296,048

	Level 1		Level 2		Level 3
2013
Assets:
Cash equivalents	$	2,066,156	$	—	$	—

Total assets at fair value	$	2,056,156	$	—	$	—


Liabilities:
Series A-1 warrants	$	—	$	—	$	438,978
Series A-2 warrants		—		—		64,537
Series C warrants		—		—		140,963

Total liabilities at fair value	$	—	$	—	$	644,478

Schedule of rollforward of fair value of Level 3 warrants

Beginning balance at December 31, 2011	$	521,525
Issuance of Series C warrants		212,976

Change in fair value		(171,013	)

Ending balance at December 31, 2012		563,488
Change in fair value		80,990

Ending balance at December 31, 2013		644,478
Expiration of Series A-1 and Series A-2 warrants		(493,361	)
Change in fair value		144,931

Ending balance at December 31, 2014	$	296,048

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Prepaid Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Prepaid Expenses

Schedule of prepaid expenses by component and classification

	December 31
	2014		2013
Prepaid clinical trial expense	$	1,677,434	$	—
Prepaid insurance		761,842		48,055
Other		41,933		98,649

Total prepaid expenses	$	2,481,209	$	146,704


Prepaid expenses, short-term	$	803,775	$	146,704
Prepaid expenses, long-term		1,677,434		—

Total prepaid expenses	$	2,481,209	$	146,704

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property and Equipment

Schedule of components of property and equipment

	December 31
	December 31						Estimated Life
	2014			2013			Estimated Life
Office equipment	$	54,468		$	51,723		3 - 10 years
Computer equipment		95,145			65,746		3 years
Manufacturing equipment		12,182,297			12,118,702		5 years

		12,331,910			12,236,171
Less: accumulated depreciation		(285,643	)		(273,092	)

Property and equipment, net	$	12,046,267		$	11,963,079

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Accrued Liabilities

Schedule of components of accrued liabilities

	December 31
	2014		2013
Employee bonuses	$	665,050	$	238,941
Accrued clinical trial costs		254,333		—
Other		142,730		140,223

Total accrued liabilities	$	1,062,113	$	379,164

Term Loan (Tables)

12 Months Ended

Dec. 31, 2014

Term Loan

Schedule of annual maturities of Term Loan

2015	$	5,105,407
2016		6,081,174
2017		3,813,419

Total	$	15,000,000

Equity Incentive Plans (Tables)

12 Months Ended

Dec. 31, 2014

Equity Incentive Plans

Schedule of stock-based compensation expense and allocation

	Year Ended December 31,
	2014		2013		2012
Employee	$	1,184,864	$	475,897	$	509,747
Non-employee		195,849		861,960		155,707

Total	$	1,380,713	$	1,337,857	$	665,454

	Year Ended December 31,
	2014		2013		2012
Research and development	$	617,061	$	861,908	$	343,990
General and administrative		763,652		475,949		311,464

Total stock-based compensation expense	$	1,380,713	$	1,337,857	$	665,454

Schedule of assumptions used to compute employee stock-based compensation

	2014			2013			2012
Risk-free interest rate		1.84	%		1.73	%		0.80	%
Expected volatility		104.8	%		104.8	%		105.2	%
Expected dividend yield		0	%		0	%		0	%
Expected life (in years)		6.25			6.25			6.25

Summary of options outstanding, vested and exercisable

	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2012		649,275		$	2.47	8.8 years
Options granted		692,456			4.38
Options cancelled/forfeited		—			—

Options outstanding at December 31, 2012		1,341,731		$	3.41	8.9 years
Options granted		27,534			4.38
Options exercised		(52,037	)		1.35
Options cancelled/forfeited		(153,607	)		4.10

Options outstanding at December 31, 2013		1,163,621			3.44	7.9 years
Options granted		712,570			8.76
Options exercised		(41,904	)		1.61
Options cancelled/forfeited		(16,739	)		4.65

Options outstanding at December 31, 2014		1,817,548			5.56	7.9 years	$	3,363,242


Options exercisable at December 31, 2014		923,301			3.34	6.8 years	$	2,999,337


Vested and expected to vest at December 31, 2014		1,817,548			5.56	7.9 years

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Taxes

Schedule of tax effects of temporary differences that give rise to significant portions of deferred tax assets

	December 31
	2014			2013
Deferred tax assets:
Net operating loss carryforwards	$	46,853,000		$	41,800,000
Research credit carryforward		3,683,000			3,110,000
Stock options and other		795,000			481,000

Total gross deferred tax assets		51,331,000			45,391,000
Valuation allowance for deferred tax assets		(51,331,000	)		(45,391,000	)

Net deferred tax assets	$	—		$	—

Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate

	December 31,
	2014			2013			2012
Federal income tax at statutory rate		34	%		34	%		34	%
State income tax benefit, net of federal benefit		6.0	%		5.7	%		5.8	%
Research and development tax credits		3.0	%		2.7	%		0.4	%
Other		—	%		(1.4	)%		(0.5	)%
Increase to valuation allowance		(24.0	)%		(41.0	)%		(39.7	)%

Effective income tax rate		19.00	%		0.00	%		0.00	%

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies.

Schedule of future minimum annual lease commitments under noncancelable operating lease

Future minimum annual lease commitments under the noncancelable operating lease in effect as of December 31, 2014 are as follows:

2015

148,729

Quarterly Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure

Summary of unaudited quarterly results of operations

	March 31, 2014		June 30, 2014			September 30, 2014			December 31, 2014
Total revenue	$	—	$	—		$	—		$	—
Operating expenses	$	2,447,626	$	3,494,710		$	6,048,884		$	6,523,996
Net income (loss)	$	839,293	$	(3,718,401	)	$	(6,353,362	)	$	(6,844,998	)
Basic net income (loss) per common share	$	0.10	$	(0.46	)	$	(0.34	)	$	(0.37	)
Diluted net income (loss) per common share	$	0.01	$	(0.46	)	$	(0.34	)	$	(0.37	)

	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Total revenue	$	—		$	—		$	—		$	—
Operating expenses	$	4,228,361		$	3,249,070		$	3,321,389		$	1,929,557
Net income (loss)	$	(4,605,416	)	$	(3,619,879	)	$	(3,690,955	)	$	(2,404,370	)
Basic net income (loss) per common share	$	(109.18	)	$	(70.29	)	$	(71.67	)	$	(45.68	)
Diluted net income (loss) per common share	$	(109.18	)	$	(70.29	)	$	(71.67	)	$	(45.68	)

Organization and Description of Business (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization and Description of Business
Accumulated deficit	$ (134,391,851)	$ (118,314,383)
Cash and cash equivalents	$ 40,182,141	$ 2,119,646	$ 20,013,754	$ 9,562,017

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References+ Details

Summary of Significant Accounting Polices (Details) (USD $)	0 Months Ended	12 Months Ended
	May 05, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 05, 2014
Stock split
Stock split conversion ratio	1.4
Par value of common stock (in dollars per share)		$ 0.0001	$ 0.0001		$ 0.0001
Deferred Financing Costs
Amortization of deferred financing costs		$ 59,100	$ 45,000	$ 0
Concentration of risk, financial assets
Financial instruments with off-balance sheet risk of accounting loss, assets		0
Concentration risk, financial liabilities
Financial instruments with off-balance sheet risk of accounting loss, liabilities		$ 0

Summary of Significant Accounting Polices (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014 segment
Warrants
Warrants outstanding	62,505
Exercise price of warrants (in dollars per share)	$ 6.00
Uncertainty in tax positions
Unrecognized Tax Benefits	$ 0
Segment Information
Number of operating segments	1

Summary of Significant Accounting Polices (Details 3)	12 Months Ended
Summary of Significant Accounting Polices (Details 3)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss per share
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	1,880,053	7,661,010	7,839,120
Redeemable Convertible Preferred Stock
Net loss per share
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)		6,292,369	6,292,369
Warrants
Net loss per share
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	62,505
Warrants \| Convertible preferred stock warrants
Net loss per share
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)		205,020	205,020
Stock options
Net loss per share
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	1,817,548	1,163,621	1,341,731

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Fair Value Measurements (Details) (USD $)				0 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended
Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014 Level 3 Warrants	Dec. 31, 2014 Level 3 Warrants Liabilities Option pricing model	Dec. 31, 2014 Level 3 Warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series A-1 warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series A-1 warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series A-2 warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series A-2 warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series C warrants Liabilities Option pricing model	Dec. 31, 2013 Level 3 Warrants Series C warrants Liabilities Option pricing model	Dec. 31, 2014 Recurring Measured at fair value Level 1	Dec. 31, 2013 Recurring Measured at fair value Level 1	Dec. 31, 2014 Recurring Measured at fair value Level 1 Cash equivalents	Dec. 31, 2013 Recurring Measured at fair value Level 1 Cash equivalents	Dec. 31, 2014 Recurring Measured at fair value Level 3	Dec. 31, 2013 Recurring Measured at fair value Level 3	Dec. 31, 2013 Recurring Measured at fair value Level 3 Warrants Series A-1 warrants	Dec. 31, 2013 Recurring Measured at fair value Level 3 Warrants Series A-2 warrants	Dec. 31, 2013 Recurring Measured at fair value Level 3 Warrants Series C warrants
Assets:
Cash and cash equivalents														$ 40,135,102	$ 2,066,156
Total assets at fair value												40,135,102	2,056,156
Liabilities:
Liability	296,048	644,478	296,048															438,978	64,537	140,963
Total liabilities at fair value																$ 296,048	$ 644,478
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants
Volatility (as a percent)				104.80%		104.80%		104.80%		104.80%
Risk free interest rate (as a percent)				1.68%		1.94%		1.94%		1.94%
Life of treasury bonds				5 years		6 years		6 years		6 years
Strike price (in dollars per share)					$ 6.00		$ 10.00		$ 10.00		$ 15.00
Fair value of stock (in dollars per share)	$ 6.14				$ 6.14		$ 4.17		$ 2.91		$ 7.63
Expected life				5 years		6 years		6 years		6 years

Fair Value Measurements (Details 2) (USD $)	12 Months Ended
Fair Value Measurements (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014 Warrants	Dec. 31, 2013 Warrants Convertible preferred stock warrants	Dec. 31, 2012 Warrants Convertible preferred stock warrants	Dec. 31, 2012 Warrants Series C warrants	Dec. 31, 2014 Warrants Series A-1 and Series A-2 warrants
Rollforward of the fair value of Level 3 warrants
Balance at the beginning of the period				$ 563,488	$ 521,525
Issuance of Series C warrants						212,976
Change in fair value			144,931	80,990	(171,013)
Balance at the end of the period			296,048	644,478	563,488
Expiration of Series A-1 and Series A-2 warrants							(493,361)
Fair value measurements
Asset transfers out of Level 1 into Level 2	0	0
Asset transfers out of Level 2 into Level 1	0	0
Asset transfers into (out of) Level 3	0	0
Liability transfers out of Level 1 into Level 2	0	0
Liability transfers out of Level 2 into Level 1	0	0
Liability transfers into (out of) Level 3	$ 0	$ 0

Prepaid Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses
Prepaid Clinical Trials	$ 1,677,434
Prepaid insurance	761,842	48,055
Other	41,933	98,649
Total prepaid expenses	2,481,209	146,704
Prepaid expenses, short-term and long-term
Prepaid expenses, short-term	803,775	146,704
Prepaid expenses, long-term	1,677,434
Total prepaid expenses	$ 2,481,209	$ 146,704

- Definition

Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References+ Details

Property and Equipment (Details) (USD $)	12 Months Ended
Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment
Property and equipment, gross	$ 12,331,910	$ 12,236,171
Less: accumulated depreciation	(285,643)	(273,092)
Property and equipment, net	12,046,267	11,963,079
Office equipment
Property and Equipment
Property and equipment, gross	54,468	51,723
Office equipment \| Minimum
Property and Equipment
Estimated Life	3 years
Office equipment \| Maximum
Property and Equipment
Estimated Life	10 years
Computer equipment
Property and Equipment
Property and equipment, gross	95,145	65,746
Estimated Life	3 years
Manufacturing equipment
Property and Equipment
Property and equipment, gross	12,182,297	12,118,702
Estimated Life	5 years
Manufacturing equipment in process of being constructed and qualified
Property and Equipment
Property and equipment, gross	$ 12,000,000	$ 11,900,000

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities
Employee bonuses	$ 665,050	$ 238,941
Accrued clinical trial costs	254,333
Other	142,730	140,223
Total accrued liabilities	$ 1,062,113	$ 379,164

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Convertible Note Financing (Details) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended	12 Months Ended
	May 29, 2014 Convertible Promissory Notes, April 2014 Common stock	Dec. 31, 2014 Convertible Promissory Notes, April 2014 Common stock	May 29, 2014 Convertible Promissory Notes, April 2014 Common stock	Apr. 28, 2014 Convertible notes Convertible Promissory Notes, April 2014
Convertible note financing
Aggregate amount of loan borrowed				$ 3.0
Interest rate (as a percent)				8.00%
Conversion of promissory notes and accrued interest (in shares)	503,450	503,450
Share price (in dollars per share)			$ 6.00

Term Loan (Details) (USD $)	12 Months Ended					1 Months Ended		12 Months Ended				12 Months Ended		1 Months Ended	12 Months Ended
Term Loan (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014 Oxford Finance loan, as amended	May 29, 2014 Conversion of Series C preferred stock warrants into common stock warrants	Jan. 31, 2014 Secured term loan Oxford Finance loan, as amended	Dec. 31, 2012 Secured term loan Oxford Finance loan, as amended	Dec. 31, 2014 Secured term loan Oxford Finance loan, as amended installment	Dec. 31, 2013 Secured term loan Oxford Finance loan, as amended	Dec. 31, 2012 Secured term loan Oxford Finance loan, as amended	Dec. 31, 2012 Secured term loan Oxford Finance loan, as amended Series C warrants Series C Preferred Stock Oxford Finance	Dec. 31, 2014 Secured term loan LIBOR Oxford Finance loan, as amended	Dec. 31, 2014 Secured term loan LIBOR Oxford Finance loan, as amended Minimum	Jan. 31, 2014 Secured term loan Interest only period Oxford Finance loan, as amended	Dec. 31, 2014 Secured term loan First twenty-four months Oxford Finance loan, as amended	Dec. 31, 2014 Secured term loan From month twenty-five to loan maturity Oxford Finance loan, as amended
Term loan
Amount borrowed			$ 15,000,000				$ 15,000,000
Fixed interest rate (as a percent)								9.20%
Variable rate basis				Three-month U.S. Libor rate
Variable rate base (as a percent)													0.47%
Variable interest rate margin (as a percent)												8.73%
Debt instrument period														12 months
Amounts paid in connection with debt agreement						150,000
Amount offset against loan to be amortized to interest expense						150,000
Number of consecutive monthly installments								30
Final payment								675,000
Prepayment premium as percentage of outstanding principal															2.00%	0.75%
Number of warrants (in shares)					62,505						25,002
Exercise price of warrants (in dollars per share)	$ 6.00				$ 6.00						$ 15.00
Value of warrants											213,000
Interest expense, including accretion of the value of the related warrants and amortization of deferred financing costs	1,565,730	1,512,911	140,051					1,545,100	1,472,300	0
Maturities of Term Loan
2015								5,105,407
2016								6,081,174
2017								3,813,419
Total								$ 15,000,000

Stockholders' Equity (Details) (USD $)	0 Months Ended			0 Months Ended							12 Months Ended		0 Months Ended	12 Months Ended	0 Months Ended		12 Months Ended
Stockholders' Equity (Details) (USD $)	May 29, 2014 class	May 29, 2014 class	Dec. 31, 2014	May 29, 2014 Minimum series	May 07, 2014 Series C Preferred Stock Automatic conversion, underwritten public offering Minimum	May 07, 2014 Series B Preferred Stock Automatic conversion, underwritten public offering Minimum	May 07, 2014 Series A-1 Preferred Stock Automatic conversion, underwritten public offering Minimum	May 07, 2014 Series A-2 Preferred Stock Automatic conversion, underwritten public offering Minimum	May 29, 2014 Convertible Promissory Notes, April 2014	May 29, 2014 Convertible Promissory Notes, April 2014 Common stock	Dec. 31, 2014 Convertible Promissory Notes, April 2014 Common stock	May 29, 2014 Convertible Promissory Notes, April 2014 Common stock	May 29, 2014 Redeemable Convertible Preferred Stock Common stock	Dec. 31, 2014 Redeemable Convertible Preferred Stock Common stock	May 29, 2014 Initial public offering	May 29, 2014 Initial public offering Common stock	Dec. 31, 2014 Initial public offering Common stock	May 29, 2014 Initial public offering Common stock
Stockholders' equity
Common stock issued (in shares)																9,166,667	9,166,667
Share price (in dollars per share)												$ 6.00						$ 6.00
Proceeds from offering, net of underwriting discounts and commissions and other offering costs															$ 49,700,000
Conversion of notes and accrued interest (in shares)										503,450	503,450
Number of common shares into which convertible preferred stock was converted													8,809,325	8,803,547
Aggregate principal amount converted									3,000,000
Gross proceeds from underwritten public offering					$ 45,000,000	$ 45,000,000	$ 45,000,000	$ 45,000,000
Authorized shares of common stock		150,000,000	150,000,000
Authorized shares of preferred stock		10,000,000
Number of series of preferred stock that may be issued				1
Number of classes of Board		3
Term of Board member	3 years
Number of classes elected at each annual meeting	1
Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)				75.00%

Stockholders' Equity (Details 2) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended			1 Months Ended
Stockholders' Equity (Details 2) (USD $)	Dec. 31, 2012	Mar. 31, 2012 Series B Preferred Stock financing, March 2012 closing Series B, 8% non-cumulative, convertible preferred stock	Dec. 31, 2012 Series B Preferred Stock financing, March 2012 closing Series B, 8% non-cumulative, convertible preferred stock	Dec. 31, 2012 Series C Preferred Stock Purchase Agreement Series C, 12% non-cumulative, convertible preferred stock	Jul. 31, 2012 Series C Preferred Stock Purchase Agreement Series C, 12% non-cumulative, convertible preferred stock Expected	Jul. 31, 2012 Series C Preferred Stock Purchase Agreement, initial tranche Series C, 12% non-cumulative, convertible preferred stock
Convertible Preferred Stock
Number of convertible preferred shares issued		253,999	253,999	1,127,746		1,578,400
Share price (in dollars per share)		$ 10.00			$ 15.00
Net proceeds from issuance of convertible preferred shares		$ 2,500,000	$ 2,536,624	$ 16,778,538		$ 22,900,000
Total shares to be issued under agreement					2,711,734
Intrinsic value on the respective commitment date for each of the series of convertible preferred stock	$ 0

- Definition

The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

Equity Incentive Plans (Details) (USD $)	12 Months Ended						12 Months Ended					12 Months Ended
Equity Incentive Plans (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2008 Amended and restated 1997 Equity Incentive Plan 1997	Dec. 31, 2014 2008 Equity Incentive Plan	Dec. 31, 2014 2014 Equity Incentive Plan	Dec. 31, 2014 Stock options	Dec. 31, 2013 Stock options	Dec. 31, 2012 Stock options	Dec. 31, 2014 Stock options Minimum	Dec. 31, 2014 Stock options Maximum	Dec. 31, 2014 Stock options Research and development	Dec. 31, 2013 Stock options Research and development	Dec. 31, 2012 Stock options Research and development	Dec. 31, 2014 Stock options General and administrative	Dec. 31, 2013 Stock options General and administrative	Dec. 31, 2012 Stock options General and administrative	Dec. 31, 2014 Employee stock options	Dec. 31, 2013 Employee stock options	Dec. 31, 2012 Employee stock options	Dec. 31, 2014 Non-employee stock options	Dec. 31, 2013 Non-employee stock options	Dec. 31, 2012 Non-employee stock options
Equity incentive plans
Expiration period																		10 years			10 years
Vesting period																		4 years			4 years
Shares available for grant				0	0	395,598
Exercise prices of options granted through the end of the year (in dollars per share)										$ 0.71	$ 1,928.57
Stock-based compensation expense	$ 1,380,713	$ 1,337,857	$ 665,454				$ 1,380,713	$ 1,337,857	$ 665,454			$ 617,061	$ 861,908	$ 343,990	$ 763,652	$ 475,949	$ 311,464	$ 1,184,864	$ 475,897	$ 509,747	$ 195,849	$ 861,960	$ 155,707
Weighted average of the assumptions used to compute employee stock based compensation
Risk-free interest rate (as a percent)																		1.84%	1.73%	0.80%
Expected volatility (as a percent)																		104.80%	104.80%	105.20%
Expected dividend yield (as a percent)																		0.00%	0.00%	0.00%
Expected life (in years)																		6 years 3 months	6 years 3 months	6 years 3 months
Unrecorded deferred stock-based compensation
Unrecorded deferred stock-based compensation balance related to stock options							$ 5,300,000
Weighted-average amortization period over which cost is expected to be recognized							1 year 11 months 23 days
Options granted
Weighted average grant date fair value of options granted (in dollars per share)							$ 7.00

Equity Incentive Plans (Details 2) (USD $)	12 Months Ended
Equity Incentive Plans (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Aggressive Intrinsic Value
Estimated stock price (in dollars per share)	$ 6.14
Stock options
Options
Options outstanding at beginning of year (in shares)	1,163,621	1,341,731	649,275
Options granted (in shares)	712,570	27,534	692,456
Options exercised (in shares)	(41,904)	(52,037)
Options cancelled/forfeited (in shares)	(16,739)	(153,607)
Options outstanding at end of year (in shares)	1,817,548	1,163,621	1,341,731	649,275
Options exercisable at end of year (in shares)	923,301
Vested and expected to vest, at end of year (in shares)	1,817,548
Weighted-Average Exercise Price
Options outstanding at beginning of year (in dollars per share)	$ 3.44	$ 3.41	$ 2.47
Options granted (in dollars per share)	$ 8.76	$ 4.38	$ 4.38
Options exercised (in dollars per share)	$ 1.61	$ 1.35
Options cancelled/forfeited (in dollars per share)	$ 4.65	$ 4.10
Options outstanding at end of year (in dollars per share)	$ 5.56	$ 3.44	$ 3.41	$ 2.47
Options exercisable at end of year (in dollars per share)	$ 3.34
Vested and expected to vest, at end of year (in dollars per share)	$ 5.56
Weighted-Average Remaining Contractual Life (Years)
Options outstanding at beginning of year	7 years 10 months 24 days	7 years 10 months 24 days	8 years 10 months 24 days	8 years 9 months 18 days
Options outstanding at end of year	7 years 10 months 24 days	7 years 10 months 24 days	8 years 10 months 24 days	8 years 9 months 18 days
Options exercisable at end of year	6 years 9 months 18 days
Vested and expected to vest, at end of year	7 years 10 months 24 days
Aggressive Intrinsic Value
Options outstanding at the end of the period (in dollars)	$ 3,363,242
Options exercisable at the end of the period (in dollars)	2,999,337
Options exercised for intrinsic value (in dollars)	$ 208,979

Income Taxes (Details 3) (USD $)	12 Months Ended
Income Taxes (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Net operating loss carryforwards	$ 46,853,000	$ 41,800,000
Research credit carryforward	3,683,000	3,110,000
Stock options and other	795,000	481,000
Total gross deferred tax assets	51,331,000	45,391,000
Valuation allowance for deferred tax assets	(51,331,000)	(45,391,000)
Deferred income tax expense or benefit	0	0
Net change in the valuation allowance, related primarily to net operating losses	$ 4,700,000	$ 6,000,000
Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate
Federal income tax at statutory rate (as a percent)	34.00%	34.00%	34.00%
State income tax benefit, net of federal benefit (as a percent)	6.00%	5.70%	5.80%
Research and development tax credits (as a percent)	3.00%	2.70%	0.40%
Other (as a percent)		(1.40%)	(0.50%)
Increase to valuation allowance (as a percent)	(24.00%)	(41.00%)	(39.70%)
Effective income tax rate (as a percent)	19.00%	0.00%	0.00%

Income Taxes (Details 4) (USD $) In Millions, unless otherwise specified				0 Months Ended
	Feb. 27, 2014 Sale of NOLs and research and development credits	Dec. 31, 2014 State	Dec. 31, 2014 State Research and development	Feb. 27, 2014 State New Jersey Sale of NOLs and research and development credits	Feb. 27, 2014 State New Jersey Research and development Sale of NOLs and research and development credits
Sale of New Jersey Net Operating Losses
NOLs	$ 39.1	$ 82.1
Tax credits			1.1		0.4
Net proceeds from sale				$ 3.6

Commitments and Contingencies (Details) (USD $)	12 Months Ended
Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014 sqft	Dec. 31, 2013	Dec. 31, 2012
Operating Leases
Area of office space leased (in square feet)	7,000
Lease term	2 years
Term of renewal option	3 years
Rent expense	$ 159,042	$ 141,854	$ 113,962
Future minimum annual lease commitments under the noncancelable operating lease
2015	$ 148,729

Subsequent Events (Details) (USD $)	12 Months Ended		1 Months Ended			1 Months Ended
Subsequent Events (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2012 Oxford Finance loan, as amended Secured term loan	Feb. 28, 2015 Subsequent Event February 2015 Loan and Security Agreement Secured term loan	Feb. 28, 2015 Subsequent Event February 2015 Loan and Security Agreement Secured term loan Hercules	Feb. 28, 2015 Subsequent Event Oxford Finance loan, as amended Secured term loan	Jan. 31, 2015 Subsequent Event Private Placement	Jan. 31, 2015 Subsequent Event Private Placement Common stock	Feb. 28, 2015 Subsequent Event Equity financings February 2015 Loan and Security Agreement Secured term loan Hercules Right to participate in future equity financings Maximum
Subsequent Events
Issuance of stock (in shares)								3,400,000
Share price (in dollars per share)								$ 5.85
Proceeds from sale of stock, net of commissions and other offering costs							$ 19,300,000
Maximum borrowing capacity				25,000,000
Amount funded	15,000,000		15,000,000	16,500,000
Repayment of existing term loan						15,500,000
Additional amount available				8,500,000
Number of warrants (in shares)					180,274
Exercise price of warrants (in dollars per share)		$ 6.00			$ 5.89
Proceeds from Issuance or Sale of Equity									$ 2,000,000

Quarterly Data (Unaudited) (USD $)	3 Months Ended								12 Months Ended
Quarterly Data (Unaudited) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Information [Abstract]
Total revenue
Operating expenses	6,523,996	6,048,884	3,494,710	2,447,626	1,929,557	3,321,389	3,249,070	4,228,361	18,515,216	12,728,377	23,316,851
Net income (loss)	$ (6,844,998)	$ (6,353,362)	$ (3,718,401)	$ 839,293	$ (2,404,370)	$ (3,690,955)	$ (3,619,879)	$ (4,605,416)	$ (16,077,468)	$ (14,320,620)	$ (23,860,127)
Basic net income (loss) per common share	$ (0.37)	$ (0.34)	$ (0.46)	$ 0.10	$ (45.68)	$ (71.67)	$ (70.29)	$ (109.18)
Diluted net income (loss) per common share	$ (0.37)	$ (0.34)	$ (0.46)	$ 0.01	$ (45.68)	$ (71.67)	$ (70.29)	$ (109.18)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

Income Taxes (Details 2) (Research and development, USD $) In Millions, unless otherwise specified	Dec. 31, 2014
State
Tax credit carryforwards
Tax credit carryforwards	$ 1.1
Federal
Tax credit carryforwards
Tax credit carryforwards	$ 2.9

Related Party Transactions (Details) (SmartPharma, Commercial and business development consulting services, USD $)	12 Months Ended
	Dec. 31, 2014
SmartPharma \| Commercial and business development consulting services
Related party transactions
Fees invoiced by the related party	$ 126,500

Income Taxes (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2014
State
Net operating loss carryforwards
Net operating loss carryforwards	$ 82.1
Federal
Net operating loss carryforwards
Net operating loss carryforwards	$ 123.3